160 likes | 285 Views
Clinical Research Information System (EHR/CR) – Functional Profile. HL7 Working Group EHR-S Technical Committee Presentation. Agenda. EHR/CR-FP Working Group Team Members eHealth (EHR) Business Realities of Drug Development The Challenge The Profile. EHR/CR-FP Working Group.
E N D
Clinical Research Information System (EHR/CR) – Functional Profile HL7 Working Group EHR-S Technical Committee Presentation
Agenda • EHR/CR-FP Working Group • Team Members • eHealth (EHR) • Business Realities of Drug Development • The Challenge • The Profile
EHR/CR-FP Working Group • Organized by the eClinical Forum and PhRMA EDC/eSource Task Force. • International Representation • Collaborative effort between bio-pharmaceutical and healthcare industries and associated vendors
EHR/CR-FP Co-chairs John D. Mestler Procter & Gamble Pharmaceuticals Suzanne Bishop SKB Consulting EHR/CR-FP Functional Profile Working Group (International Group) Seema Bhat Bayer Paul Brandon Siemens Medical Solutions Robert Case Procter & Gamble Pharmaceuticals Catherine Celingant Millennium Pharmaceuticals Gary Drucker Bayer Patricia Gregory Boehringer Ingelheim Jane Griffin Cerner Corporation Ian Hamilton Eli Lilly Darlene KalinowskiBristol Myers Squib Linda King Eli Lilly Marie MacDonald ClinPhone Richard Perkins Concept Consulting Mathias Poensgen Altana Pharmaceuticals Christian Reich Millennium Pharmaceuticals Vincente Rodriguez Eli Lilly Miguel Valenzuela Roche
eHealth is Driven by the need to… Enhance patient safety Improve quality of healthcare Reduce healthcare costs eHealth is About… • Bringing information and knowledge to the point of care • Realizing this across boundaries • Moving from specialist-centric to patient-centric information
The Facts Innovation of medicines is a high-risk business Less than 9% of clinical candidates make it to patients The cost and timescale of innovative medicine has escalated A new molecule can cost $750M -$1.0B and takes 11-15 years to develop Research $ focused where there is a ROI The Results Failure to innovate is leading to fewer new innovative medicines reaching the patient Failure to control cost and move fast enough is leading to more expensive and late therapies Potential medicines not reaching the patient and niche markets of high medical need not being explored Business Realities of Drug Development
DATA DATA ATA ATA DATA DATA ePROWeb Server CDMS Electronic Data Capture (EDC) Site EDC Web Server Archive & Submission Source Subject Reporting ePRO Paper Labs ECG
The Challenge … Approaches To Clinical Trial Data Capture At Investigator Sites Patient visit Historical Paper Medical Record Paper CRF Research Database Healthcare Research Emerging but Duplicative Paper or Electronic Medical Record Electronic CRF, ePRO, Labs Research Database EDC Hosted Data Future Integration EHR-S Electronic Health Record Trial Specific Data Research Database Trial With the increased use of EHR / EMR, the Emerging EDC Environment Results In… increased effort, cost, possibility of questionable authenticity
The Challenges … Standards Common data standards allow movement of data between healthcare and research Systems Reliable, validated systems meet healthcare and research requirements Future Connected Healthcare & Research Process Controlled process for release and transfer of datameets bio-ethical concerns Results In… Minimized effort and cost, better data quality, improved drugsafety,greater research opportunity
EHR/CR Profile Description • Establishes requirements, non-redundant functions, processes to use patient electronic medical data for clinical research. • Ensures that data protection, regulatory, and ethical research requirements are met. • Minimizes the challenges of clinical research for healthcare professionals. • Endorses data standards (CDISC/HL7) for data collection, interpretation and exchange within the medical and research communities. • Expand and adapt functions of EHR and the associated systems, networks, and processes
Profile Objective • Develop an HL7 Informative Functional Profile that identifies critical capabilities for clinical research utilizing EHR systems. • Establish conformance to the HL7 EHR Functional Model, under the auspices and direction of the EHR Technical Committee. • Provide EHR vendors conformance criteria that are specific to Clinical Research. • Encourage incorporation of the functions necessary to utilize the Electronic Health Records as the direct data source for clinical studies. • Define additional functions that may be required and have not yet been included within existing functional models. • International Profile
Profile Phases The project is planned in four phases: • Organization • participants, determination of • scope • care setting • Project Plan • Formalization –EHR/CR-FP functions and conformance criteria (in process) . • Harmonization – comparison, incorporation, and alignment with the EHR FM (in process) . • Finalization – Conformance and preparation for final EHR – TC approval and external publication.
Profile – Essential Now (EN) • Ensure that patient data from an EHR system will meet clinical research regulatory requirements for data collection, management, extraction, security, and can be interpreted in a consistent manner. • Functions must be present to use EHR data for clinical research without redundant re-keying and verifying Note: If we can think of a reasonable work-around we can move function into the essential future
Profile – Essential Future • Functions needed to improve efficiency and performance • Functions necessary to ultimately conduct all clinical research data capture and management through nation-wide health information networks and systems. • Functions will be divided into levels along the evolution to this ultimate goal. None of the EF functions will be required to be present on “day 1” of using the EHR data for clinical research. (Sponsors can provide work-arounds either through processes or sponsor-supplied electronic systems).
Profile – Essential Future Examples of Possible Future Functions • The function should support data checking (i.e., for reasonableness as defined by the trial sponsor) • Electronic signature capability in compliance with Part 11